I've previously talked about how certain cooties in our gut can serve us well in all sorts of ways. There was even a study noted in this link:
Cooties in our gut keep us skinny, smart, and cure cancer? that found Bifidobacterium could promote antitumor immunity and facilitate anti-PD-L1 efficacy! Now there is this:
Intestinal microbiome analyses identify melanoma
patients at risk for checkpoint-blockade-induced colitis. Dubin, Callahan, Ren, Wolchok, et al. Nat Commun. 2016 Feb 2.
The composition of the intestinal microbiota
influences the development of inflammatory disorders. However, associating
inflammatory diseases with specific microbial members of the microbiota is
challenging, because clinically detectable inflammation and its treatment can
alter the microbiota's composition. Immunologic checkpoint blockade with
ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated
colitis. Here we conduct a prospective study of patients with metastatic
melanoma undergoing ipilimumab treatment and correlate the pre-inflammation
faecal microbiota and microbiome composition with subsequent colitis
development. We demonstrate that increased representation of bacteria belonging
to the Bacteroidetes phylum is correlated with resistance to the development of
checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways
involved in polyamine transport and B vitamin biosynthesis is associated with
an increased risk of colitis. Identification of these biomarkers may enable
interventions to reduce the risk of inflammatory complications following cancer
immunotherapy.
It would certainly be helpful to have a head's up about who is more at risk for the development of colitis when treated with immunotherapy! Perhaps other options would serve the patient better or if immunotherapy is undertaken anyway, a prior warning could promote a more watchful eye and aggressive, prompt treatment should any adverse symptoms appear. Best - c
No comments:
Post a Comment